The burden of atopic dermatitis (AD) -- for patients, their families, and society -- is vast and increasing. AD affects approximately 10% to 30% of children and 2% to 10% of adults in developed ...
Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment. Trial investigator Emma Guttman, MD, PhD, chair of ...
Among the strong points of Nektar Therapeutics Inc.’s atopic dermatitis (AD) prospect, rezpegaldesleukin (rezpeg), an IL-2 pathway agonist and regulatory T-cell proliferator, is the drug’s faster ...
Please provide your email address to receive an email when new articles are posted on . Tremfya (guselkumab) is an interleukin-23 inhibitor. The submissions are supported by clinical and ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U ...
SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ...
Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the treatment of solid tumors. APVO603 is a novel bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results